Canopy Growth vs Cronos
CGC and CRON side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGC and CRON compare
Cronos grew revenue faster over the last twelve months (55.8% versus 10.7% for Canopy Growth).
Cronos keeps more of each dollar of sales as profit, with a net margin of 28.0% compared with −87.0% at Canopy Growth.
Cronos scores higher on the StockData Score (15 against 3 for Canopy Growth), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGC | CRON |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.3B |
| Share price | $0.605 | $3.45 |
| Change, 1 year | −52.4% | 34.8% |
| Change, 5 years | −99.5% | −30.0% |
| Beta (5Y) | 1.91 | 0.85 |
| Employees | 1,128 | 610 |
| StockData Score | ||
| Total score | 3 | 15 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 20.3× |
| P/S | – | 6.2× |
| P/B | – | 1.2× |
| EV/EBITDA | – | 38.3× |
| P/FCF | – | 19.4× |
| FCF yield | – | 5.1% |
| Fair value | – | $3.66 |
| Margin of safety | – | 5.7% |
| Growth | ||
| Revenue growth (TTM) | 10.7% | 55.8% (better) |
| Revenue growth, 5Y average | −12.2% | 25.7% (better) |
| Net income growth (TTM) | – | 60.2% |
| EPS growth (TTM) | – | 70.0% |
| Profitability | ||
| Gross margin | 24.4% | 46.6% (better) |
| Operating margin | −54.2% | 3.4% (better) |
| Net margin | −87.0% | 28.0% (better) |
| FCF margin | −25.8% | 31.7% (better) |
| Return on equity | – | 5.4% |
| Return on invested capital | – | 2.4% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −3.7× | – |
| Current ratio | 2.82 | 12.71 (better) |
| Altman Z-score | – | 11.97 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 3.7% |
| Shareholder yield | – | 3.7% |
| Ownership | ||
| Held by institutions | 6.9% | 12.9% |
| Held by insiders | 1.0% | 7.0% |
| Insider net buying, 12 months | −$393K | – |
| Short interest, % of float | – | 1.2% |
Go deeper
- CGC stock overview
- CGC income statement
- CGC valuation and score
- CRON stock overview
- CRON income statement
- CRON valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.